Home › Multiple Myeloma › Texas › Dallas
Pag-aaral pangklinika para sa Multiple Myeloma sa Dallas, TX
Isang pag-aaral para sa Multiple Myeloma ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Dallas. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Nagre-recruitPhase 3
- Baylor University Medical Center, Investigational Drug Services, Department of Pharmacy, Dallas
- Baylor University Medical Center, Dallas
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 1
- Texas Oncology - Dallas - Worth Street /ID# 280064, Dallas
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Nagre-recruitPhase 1
- University of Texas Southwestern, Dallas
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Nagre-recruitPhase 3
- University of Texas Southwestern Medical Center, Dallas
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 3
- Baylor University Medical Center, Dallas
- UT Southwestern Medical Center, Dallas
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
Nagre-recruitPhase 1
- Baylor University Medical Center, Dallas
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Nagre-recruitPhase 1/2
- University of Texas - Southwestern Medical Center /ID# 271914, Dallas
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Nagre-recruitPhase 1
- University of Texas Southwestern Harold C. Simmons Comprehensive Cancer Center, Dallas
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
Nagre-recruitPhase 3
- Research Site, Dallas
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Nagre-recruitPhase 1/2
- University of Texas - Southwestern Medical Center /ID# 274360, Dallas
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Nagre-recruitPhase 1/2
- Research Site, Dallas
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 2
- UT Southwestern Medical Center, Dallas
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Nagre-recruitPhase 3
- Research Site, Dallas
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 3
- Baylor University Medical Center, Dallas
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Nagre-recruitPhase 3
- Research Site, Dallas
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
Nagre-recruitPhase 2
- University of Texas Southwestern, Dallas
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
Nagre-recruitObservasyonal na pag-aaral
- Ut Southwestern, Dallas
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Nagre-recruitPhase 1
- University of Texas Southwestern Medical Center, Dallas
Pag-aaral para sa Multiple Myeloma sa ibang lungsod
- New York City, NY59 pag-aaral
- Boston, MA45 pag-aaral
- Atlanta, GA42 pag-aaral
- Houston, TX39 pag-aaral
- Durham, NC36 pag-aaral
- Nashville, TN31 pag-aaral
- Denver, CO26 pag-aaral
- St. Louis, MO26 pag-aaral
- Rochester, MN25 pag-aaral
- Columbus, OH25 pag-aaral
- Chicago, IL24 pag-aaral
- Milwaukee, WI23 pag-aaral
Iba pang pag-aaral sa Dallas
- Kanser sa Suso54 pag-aaral
- Non-Small Cell Lung Cancer53 pag-aaral
- Metastatic Cancer44 pag-aaral
- Pagkabigo ng Puso42 pag-aaral
- Kanser (lahat ng uri)40 pag-aaral
- Kanser sa Prostate39 pag-aaral
- Colorectal Cancer34 pag-aaral
- Obesity33 pag-aaral
- Kanser sa Ovary31 pag-aaral
- Kanser sa Pantog27 pag-aaral
- Kanser sa Baga26 pag-aaral
- Kanser ng Endometrium25 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.